Compare MOD & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOD | COGT |
|---|---|---|
| Founded | 1916 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.5B |
| IPO Year | N/A | 2018 |
| Metric | MOD | COGT |
|---|---|---|
| Price | $146.02 | $36.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $177.60 | $32.08 |
| AVG Volume (30 Days) | 1.3M | ★ 2.4M |
| Earning Date | 02-04-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.04 | N/A |
| EPS | ★ 3.47 | N/A |
| Revenue | ★ $2,685,700,000.00 | N/A |
| Revenue This Year | $19.10 | N/A |
| Revenue Next Year | $15.40 | N/A |
| P/E Ratio | $42.07 | ★ N/A |
| Revenue Growth | ★ 8.10 | N/A |
| 52 Week Low | $64.79 | $3.72 |
| 52 Week High | $166.94 | $43.73 |
| Indicator | MOD | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 58.12 | 48.18 |
| Support Level | $122.21 | $37.70 |
| Resistance Level | $150.75 | $40.40 |
| Average True Range (ATR) | 8.05 | 1.93 |
| MACD | 2.76 | 0.09 |
| Stochastic Oscillator | 87.57 | 45.61 |
Modine Manufacturing Co provides thermal management solutions to diversified markets and customers. The company provides engineered heat transfer systems and heat transfer components for use in on- and off-highway original equipment manufacturer (OEM) vehicular applications in the United States. It offers powertrain cooling products, such as engine cooling assemblies, radiators, condensers, and charge air coolers; auxiliary cooling products, including power steering and transmission oil coolers. Its operating segments include Climate Solutions and Performance Technologies.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.